An Open-Label Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

    Not Recruiting
  • End date
    Oct 29, 2021
  • participants needed
  • sponsor
    Incyte Corporation
Updated on 25 April 2021
Incyte Corporation Call Center
Primary Contact
Hosptial Univeritario Quiron Madrid (3.7 mi away) Contact
+79 other location
follicular lymphoma


The purpose of this study is to assess the objective response rate of parsaclisib treatment in subjects with relapsed or refractory follicular lymphoma.

Condition Follicular Lymphoma, Lymphoma, Lymphoma
Treatment INCB050465, Idelalisib, Parsaclisib
Clinical Study IdentifierNCT03126019
SponsorIncyte Corporation
Last Modified on25 April 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note